Brief: Amplia Therapeutics Says Results From Phase 1 Trial Confirm Amp945 Is Safe And Well Tolerated
Nov 18 (Reuters) - Amplia Therapeutics Ltd ATX.AX :
* AMPLIA THERAPEUTICS LTD - UNBLINDED RESULTS FROM PHASE 1 TRIAL CONFIRM
AMP945 IS
SAFE AND WELL TOLERATED AT ALL DOSES TESTED
Source text for Eikon: ID:nASX3Jrh39
Further company coverage: ATX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement